TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02480166
Drug: 12 weeks SOF/LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Study: NCT00422149
Drug: SUBLIVAC® Grasses/Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUBLIVAC® Grasses/Placebo treatment
Study: NCT00422149
Drug: SUBLIVAC® Grasses treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUBLIVAC® Grasses treatment
Study: NCT00422149
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT01349140
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
Study: NCT02130414
Drug: Sandimmun® IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg IV
Study: NCT02130414
Drug: CyCol® capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg CyCol® capsules
Study: NCT01689714
Drug: Tc 99m EC20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01049165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day
Study: NCT00024427
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High dose 5-FU
Study: NCT04088448
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
Study: NCT02862691
Drug: Acetaminophen/Oxycodone (Oral analgesic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
Study: NCT00895414
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT03786302
Drug: TAMP bioglass
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Study: NCT03786302
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Study: NCT00521430
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00585221
Drug: Peginterferon-alpha 2b (PegIFNa2b);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
Study: NCT00068250
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
Study: NCT00908869
Drug: Vinorelbine, Cyclophosphamide and Interferon alpha 2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week .
Study: NCT00174863
Drug: SR31747A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03832114
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of LNP023 up to 200 mg.
Study: NCT00931723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment twice daily.
Study: NCT03937648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01683006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.
Study: NCT04600505
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.
Study: NCT04600505
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.
Study: NCT04134247
Drug: PD-1 combined with chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Study: NCT03352557
Drug: BIIB092
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in treatment arm.
Study: NCT03352557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in treatment arm.
Study: NCT00907803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, once daily for 14 days
Study: NCT02995083
Drug: Normal Saline 10 ml
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
Study: NCT00888355
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to losartan tablet q.a.m. , for 12 weeks
Study: NCT01448824
Drug: LY2484595
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01448824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04338724
Drug: CS1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT02378194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks, once daily oral administration
Study: NCT02378194
Drug: HD-003 (800mg/day)
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks, once daily oral administration
Study: NCT02378194
Drug: HD-003 (1600mg/day)
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks, once daily oral administration
Study: NCT00586365
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Naproxen twice a day for two weeks
Study: NCT03633630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Study: NCT00539513
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
Study: NCT00004206
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004206
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004206
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00092872
Drug: MK0557
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02427568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
Study: NCT00929188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
Study: NCT02029716
Drug: RTA 408 Lotion 0.5%, 1%, 3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02029716
Drug: Lotion vehicle/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02994953
Drug: M9241 (MTD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
Study: NCT04627181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
Study: NCT04627181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
Study: NCT02304926
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin (40 mg/day) for 4 weeks
Study: NCT00964340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
Study: NCT00964340
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
Study: NCT02304926
Drug: Simvastatin + Ezetimibe
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
Study: NCT03649152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02118766
Drug: AN2728 Topical Ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02118766
Drug: Matching vehicle control
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03011970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Study: NCT00010387
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01057225
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03746691
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Study: NCT02229214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181361
Drug: hirudin plus aspirin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
Study: NCT01571284
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan, 5-FU and leucovorin
Study: NCT02202512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT02202512
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01608217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (tablet) three times daily for a period of three weeks.
Study: NCT01608217
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg three times daily for a period of 3 weeks
Study: NCT01608217
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg three times daily for a period of three weeks
Study: NCT00529126
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKY0402
Study: NCT04213781
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 µg/kg
Study: NCT02739529
Drug: Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor EL-free polymeric micelle of paclitaxel
Study: NCT00278902
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT00241631
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00241631
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline placebo capcule
Study: NCT06413420
Drug: Other prescription wake-promoting medications or stimulants
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
Study: NCT01118520
Drug: perindopril arginine
Normalized name: Perindopril Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mgs orally daily for the duration of the trial
Study: NCT01118520
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one daily
Study: NCT04025593
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2 day 1
Study: NCT04025593
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2 day 1
Study: NCT01185418
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01279629
Drug: Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
Study: NCT02345772
Drug: Trastuzumab (H, 8mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study: NCT04134247
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Study: NCT02345772
Drug: Pertuzumab (P, 840 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study: NCT01170065
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose BIBF 1120 twice daily
Study: NCT01170065
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose BIBF 1120 twice daily
Study: NCT01170065
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BIBF 1120 twice daily
Study: NCT01170065
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BIBF 1120 once daily
Study: NCT01913028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
Study: NCT03042377
Drug: Multiple-Visit-Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
Study: NCT03042377
Drug: Multiple-Visit-Antibiotic Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
Study: NCT00770042
Drug: Erythomycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
Study: NCT01151735
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03933410
Drug: KB195
Normalized name: Ketobemidone
DrugBank: Ketobemidone (DB06738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB195 is a novel glycan
Study: NCT04397913
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
Study: NCT00686322
Drug: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Study: NCT01716338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025428
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025428
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02692040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT04084548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative placebo infusion (normal saline)
Study: NCT01760330
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01760330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01476189
Drug: Experimental paracetamol formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental
Study: NCT01476189
Drug: Marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed paracetamol
Study: NCT01476189
Drug: Higher dose marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose marketed paracetamol
Study: NCT00712530
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study: NCT02579265
Drug: Intralipid® 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein.
Study: NCT04218838
Drug: Intra-articular Sacroiliac Joint Steroid Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care - Steroid injection into the sacroiliac joint
Study: NCT00387413
Drug: GSK189254
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
Study: NCT00387413
Drug: GSK189254 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
Study: NCT00433056
Drug: stable HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous therapy
Study: NCT04894643
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant to proton-radiotherapy (on the same days, within week 14-19)